Defiance Junior Biotech ETF (IBBJ)
| Assets | $7.12M |
| NAV | $28.49 |
| Expense Ratio | 0.45% |
| PE Ratio | n/a |
| Shares Out | 250,000 |
| Dividend (ttm) | $0.30 |
| Dividend Yield | 1.05% |
| Ex-Dividend Date | Dec 29, 2020 |
| 1-Year Return | - |
| Volume | 2,108 |
| Open | 28.44 |
| Previous Close | 28.47 |
| Day's Range | 28.05 - 28.55 |
| 52-Week Low | 26.78 |
| 52-Week High | 41.45 |
| Beta | -2.60 |
| Holdings | 232 |
| Inception Date | Aug 3, 2020 |
About IBBJ
The investment seeks to track the total return performance, before fees and expenses, of the NASDAQ Junior Biotechnology Index. The index is a rules-based index that consists of a portfolio of the stock of U.S.-listed small capitalization (junior) companies screened from the universe of the NASDAQ Biotechnology Index. The fund will generally use a replication strategy to achieve its investment objective, meaning it will generally invest in all of the component securities of the index in the same approximate proportions as in the index. The fund is non-diversified.
Top 10 Holdings
20.86% of assets| Name | Symbol | Weight |
|---|---|---|
| Intellia Therapeutics | NTLA | 3.07% |
| Zai Lab | ZLAB | 2.24% |
| BridgeBio Pharma | BBIO | 2.20% |
| Medpace Holdings | MEDP | 2.18% |
| Beam Therapeutics | BEAM | 2.03% |
| Twist Bioscience | TWST | 1.88% |
| Kodiak Sciences | KOD | 1.88% |
| Fate Therapeutics | FATE | 1.84% |
| Allakos | ALLK | 1.79% |
| Halozyme Therapeutics | HALO | 1.76% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 22, 2021 | $0.000 | Sep 24, 2021 |
| Jun 23, 2021 | $0.000 | Jun 25, 2021 |
| Mar 24, 2021 | $0.000 | Mar 26, 2021 |
| Dec 29, 2020 | $0.29981 | Dec 31, 2020 |
News
Biotech ETFs Benefit From Moderna Dual Booster Shot News
As the stock market attempts to reverse the recent pullback this month, Moderna shares climbed higher on Thursday after the company announced that it's creating a dual-purpose vaccine booster shot that ...
Could Biotech ETFs Get Another Boost From JNJ News?
This has been a pivotal week for biotech news, as Johnson & Johnson said Wednesday that a booster shot of its COVID-19 vaccine generated a promising immune response in early stage clinical trials. This ...
When Will Smaller Biotech Firms Get Their Big Break?
Smaller biotechnology stocks aren't setting the world on fire this year, but some analysts believe it's a matter of when, not if, that situation reverses. Should small biotechnology names get their resp...
Biotech ETFs Are Already Benefitting from Pfizer Vaccine's Full Approval
There could be big gains ahead for biotech ETFs, as the Food and Drug Administration on Monday fully approved the Pfizer and BioNTech coronavirus vaccine, making it the first vaccine in the U.S. to be a...
Bet on Biotech Small Caps to Bounce Back
Large cap biotechnology have strengthened in recent months, but smaller counterparts are still waiting on their 2021 moment. When that happens, the Defiance Nasdaq Junior Biotechnology ETF (IBBJ) could ...
Why Small Cap Biotech ETFs Are Still Brilliant Bets
Small cap stocks are retreating. So are biotechnology names.
Consider Smaller Biotech ETFs as Big Pharma Goes Shopping in 2021
After a lull in mergers and acquisitions activity, Big Pharma could begin to use its cash stores to buy out smaller targets, potentially fueling the momentum in biotechnology-related exchange traded fun...
New Biotech ETF Quick To Strut Its Stuff
There are recipes for success for new exchange-traded funds. In an effort to attract assets and investors' attention, rookie ETFs can undercut established rivals on fees, offer exposure to a compelling ...
Young But Hungry: A New Defiance ETF is Defying Expectations
The Defiance Nasdaq Junior Biotechnology ETF (IBBJ) is just a few months in, but it's already asserting itself in the biotechnology exchange traded funds arena, one teeming with competition. IBBJ tracks...
IBBJ ETF, the Junior Biotech ETF Outperforming Nasdaq Biotechnology Index
NEW YORK--(BUSINESS WIRE)---- $IBBJ #Biotech--About Defiance: Founded in 2018, Defiance ETFs is an exchange-traded funds (ETFs) sponsor and registered investment advisor, focused on thematic investing. ...
"Worst September in 18 Years"? 4 Sector ETFs Surviving Selloffs
After a superb August, September looks gloomy for Wall Street. Still,
Healthcare ETFs, Stocks That Gained Double Digits Last Week
The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.
4 Best-Performing Sector ETFs of Last Week
The S&P 500, the Dow Jones and the Nasdaq Composite have lost about 0.6%, 0.03% and 0.6%, respectively, past week.
3 ETFs To Play Gilead's $21B Immunomedics Takeover
Biotechnology mergers and acquisitions appear to be back in a big way with news that Gilead Sciences (NASDAQ: GILD) is acquiring Immunomedics (NASDAQ: IMMU) for $21 billion.
Small-Cap Biotechnology ETF Brings Big Opportunity
The Defiance Nasdaq Junior Biotechnology ETF (IBBJ) is still in its infancy in the biotechnology ETFs arena, having debuted just last month, but a big opportunity comes with this rookie ETF. IBBJ tracks...
This Baby Biotech ETF Has Big Potential
The Defiance Nasdaq Junior Biotechnology ETF (NYSE: IBBJ) is the newest addition to the biotechnology exchange traded funds fray, having debuted about a month ago.
Why Small-Cap Biotech ETFs Are Good Long-Term Bets
Small-cap biotech ETFs may prove to be winning bets with or without coronavirus.
ETF of the Week: Defiance Nasdaq Junior Biotechnology ETF (IBBJ)
ETF Trends CEO Tom Lydon discussed the Defiance Nasdaq Junior Biotechnology ETF (IBBJ) on this week’s “ETF of the Week” podcast with Chuck Jaffe on the MoneyLife Show. IBBJ covers companies around the g...
A Junior Biotech ETF With Home Run Potential
The Defiance Nasdaq Junior Biotechnology ETF (IBBJ) is one of the newest exchange traded funds on the market and it could be one of the most appropriate for the current environment. IBBJ’s 176 member fi...
New Biotech ETF Taps Into Small But Mighty Theme
Extending what’s been a busy stretch of unique healthcare ETF launches, the Defiance Nasdaq Junior Biotechnology ETF (IBBJ) debuted on Tuesday, coming to market at a time when biotechnology ETFs, broadl...
Hey, Junior: New Biotech ETF Goes Small In Search Of Big Winners
With significant help from the fight against the coronavirus, biotechnology stock and exchange-traded funds are setting torrid paces this year.
Defiance Debuts Nasdaq Junior Biotechnology ETF (IBBJ)
Defiance ETFs debuted a new ETF today with targeted exposure to the junior disruptors in the biotech space.